Drugs to be Discontinued

Companies are required under Section 506C of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (as amended by the Food and Drug Administration Safety and Innovation Act) to notify FDA of a permanent discontinuance of certain drug products, six months in advance, or if that is not possible, as soon as practicable. These drugs include those that are life-supporting, life-sustaining or for use in the prevention or treatment of a debilitating disease or condition, including any such drug used in emergency medical care or during surgery). The discontinuations provided below reflect information received from manufacturers, and are for informational purposes only.

Data and Resources

Field Value
accessLevel public
bureauCode {009:10}
catalog_@context https://project-open-data.cio.gov/v1.1/schema/catalog.jsonld
catalog_@id https://healthdata.gov/data.json
catalog_conformsTo https://project-open-data.cio.gov/v1.1/schema
catalog_describedBy https://project-open-data.cio.gov/v1.1/schema/catalog.json
identifier 6e72c239-0510-49f4-8404-d3d7d50351ec
issued 2025-01-29
landingPage http://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm050794.htm
license http://opendefinition.org/licenses/odc-odbl/
modified 2013-09-26
programCode {009:002}
publisher U.S. Food and Drug Administration
resource-type Dataset
source_datajson_identifier true
source_hash e55b0e1ff8d060cb7b25160f8fee0bc8c949796fdf061052096de17df1d1692d
source_schema_version 1.1
theme {FDA}
Groups
  • AmeriGEOSS
  • National Provider
  • North America
Tags
  • AmeriGEO
  • AmeriGEOSS
  • CKAN
  • GEO
  • GEOSS
  • National
  • North America
  • United States
  • cder
  • discontinued-drugs
isopen False
license_id other-license-specified
license_title other-license-specified
maintainer openFDA
maintainer_email open@fda.hhs.gov
metadata_created 2025-09-23T18:11:14.202972
metadata_modified 2025-09-23T18:11:14.202978
notes Companies are required under Section 506C of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (as amended by the Food and Drug Administration Safety and Innovation Act) to notify FDA of a permanent discontinuance of certain drug products, six months in advance, or if that is not possible, as soon as practicable. These drugs include those that are life-supporting, life-sustaining or for use in the prevention or treatment of a debilitating disease or condition, including any such drug used in emergency medical care or during surgery). The discontinuations provided below reflect information received from manufacturers, and are for informational purposes only.
num_resources 1
num_tags 10
title Drugs to be Discontinued